Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Quigley

Showing results (711-720 of 748) with videos related to

Pageof 75
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 31, 2020
Copy Number Loss of 17q22 Is Associated with Enzalutamide Resistance and Poor Prognosis in Metastatic Castration-Resistant Prostate CancerXiangnan Guan, Duanchen Sun, Eric Lu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 25, 2024
Synthetic Lethal Targeting of CDK12-Deficient Prostate Cancer with PARP InhibitorsJonathan Chou, Troy M Robinson, Emily A Egusa, et al.
Genome Biology|April 16, 2026
Convergent evolution of complex structural variants drives therapy resistance in metastatic prostate cancerThaidy Moreno-Rodriguez, Meng Zhang, Arian Lundberg, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 22, 2018
Clinical and Genomic Implications of Luminal and Basal Subtypes Across CarcinomasShuang G Zhao, William S Chen, Rajdeep Das, et al.
The Oncologist|June 22, 2024
HER2 overexpression in urothelial carcinoma with GATA3 and PPARG copy number gainsXiaolin Zhu, Emily Chan, Michelle L Turski, et al.
Molecular Cancer Research : MCR|February 13, 2018
Antisecretory Factor-Mediated Inhibition of Cell Volume Dynamics Produces Antitumor Activity in GlioblastomaShirin Ilkhanizadeh, Hanna Sabelström, Yekaterina A Miroshnikova, et al.
Cell Reports|December 2, 2014
Expression quantitative trait loci and receptor pharmacology implicate Arg1 and the GABA-A receptor as therapeutic targets in neuroblastomaChristopher S Hackett, David A Quigley, Robyn A Wong, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 5, 2021
IgE blockade with omalizumab reduces pruritus related to immune checkpoint inhibitors and anti-HER2 therapiesD M Barrios, G S Phillips, A N Geisler, et al.
Cancer Research|January 14, 2026
A Double-Negative Prostate Cancer Subtype is Vulnerable to SWI/SNF-Targeting Degrader MoleculesPhillip Thienger, Irene Paassen, Xiaosai Yao, et al.
Biorxiv : the Preprint Server for Biology|September 15, 2025
A double-negative prostate cancer subtype is vulnerable to SWI/SNF-targeting degrader moleculesPhillip Thienger, Irene Paassen, Xiaosai Yao, et al.
Pageof 75

Showing results (711-720 of 748) with videos related to

Sort By:
Pageof 75
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 31, 2020
Copy Number Loss of 17q22 Is Associated with Enzalutamide Resistance and Poor Prognosis in Metastatic Castration-Resistant Prostate CancerXiangnan Guan, Duanchen Sun, Eric Lu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 25, 2024
Synthetic Lethal Targeting of CDK12-Deficient Prostate Cancer with PARP InhibitorsJonathan Chou, Troy M Robinson, Emily A Egusa, et al.
Genome Biology|April 16, 2026
Convergent evolution of complex structural variants drives therapy resistance in metastatic prostate cancerThaidy Moreno-Rodriguez, Meng Zhang, Arian Lundberg, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 22, 2018
Clinical and Genomic Implications of Luminal and Basal Subtypes Across CarcinomasShuang G Zhao, William S Chen, Rajdeep Das, et al.
The Oncologist|June 22, 2024
HER2 overexpression in urothelial carcinoma with GATA3 and PPARG copy number gainsXiaolin Zhu, Emily Chan, Michelle L Turski, et al.
Molecular Cancer Research : MCR|February 13, 2018
Antisecretory Factor-Mediated Inhibition of Cell Volume Dynamics Produces Antitumor Activity in GlioblastomaShirin Ilkhanizadeh, Hanna Sabelström, Yekaterina A Miroshnikova, et al.
Cell Reports|December 2, 2014
Expression quantitative trait loci and receptor pharmacology implicate Arg1 and the GABA-A receptor as therapeutic targets in neuroblastomaChristopher S Hackett, David A Quigley, Robyn A Wong, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 5, 2021
IgE blockade with omalizumab reduces pruritus related to immune checkpoint inhibitors and anti-HER2 therapiesD M Barrios, G S Phillips, A N Geisler, et al.
Cancer Research|January 14, 2026
A Double-Negative Prostate Cancer Subtype is Vulnerable to SWI/SNF-Targeting Degrader MoleculesPhillip Thienger, Irene Paassen, Xiaosai Yao, et al.
Biorxiv : the Preprint Server for Biology|September 15, 2025
A double-negative prostate cancer subtype is vulnerable to SWI/SNF-targeting degrader moleculesPhillip Thienger, Irene Paassen, Xiaosai Yao, et al.
Pageof 75